Relationships between adipokines, biomarkers of endothelial function and inflammation and risk of type 2 diabetes.

[1]  J. Pankow,et al.  Novel Risk Factors and the Prediction of Type 2 Diabetes in the Atherosclerosis Risk in Communities (ARIC) Study , 2012, Diabetes Care.

[2]  I. Janszky,et al.  Metabolic factors and high-sensitivity C-reactive protein: the HUNT study , 2012, European journal of preventive cardiology.

[3]  Karel G M Moons,et al.  Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study , 2012, BMJ : British Medical Journal.

[4]  N. Sattar.  Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[5]  H. Amièva,et al.  French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial. , 2011, The American journal of clinical nutrition.

[6]  Chi-Hong Tseng,et al.  The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women: the Women's Health Initiative Observational Study. , 2010, Archives of internal medicine.

[7]  C. Meisinger,et al.  Associations between leptin and the leptin / adiponectin ratio and incident Type 2 diabetes in middle‐aged men and women: results from the MONICA / KORA Augsburg Study 1984–2002 , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[8]  Sébastien Czernichow,et al.  Microvascular dysfunction in healthy insulin-sensitive overweight individuals , 2010, Journal of hypertension.

[9]  P. Galan,et al.  Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults. , 2009, The American journal of clinical nutrition.

[10]  E. Ding,et al.  Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. , 2009, JAMA.

[11]  Jean Tichet,et al.  Predicting Diabetes: Clinical, Biological, and Genetic Approaches , 2008, Diabetes Care.

[12]  B. Zinman,et al.  Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. , 2008, Diabetes care.

[13]  N. Sattar,et al.  Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? , 2008, Diabetologia.

[14]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[15]  J. Eckel,et al.  Monocyte chemotactic protein-1 and its role in insulin resistance , 2007, Current opinion in lipidology.

[16]  Theo Stijnen,et al.  Genetic Variation, C-Reactive Protein Levels, and Incidence of Diabetes , 2007, Diabetes.

[17]  M. Quon,et al.  Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction , 2007, Current opinion in lipidology.

[18]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[19]  E. Barrett-Connor,et al.  Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. , 2006, American journal of epidemiology.

[20]  P. Galan,et al.  Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. , 2006, The American journal of clinical nutrition.

[21]  J. Pankow,et al.  Leptin and incident type 2 diabetes: risk or protection? , 2006, Diabetologia.

[22]  E. Barrett-Connor,et al.  Cardiovascular Death and the Metabolic Syndrome , 2006, Diabetes Care.

[23]  C. Meisinger,et al.  Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984–2002 , 2006, Diabetologia.

[24]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[25]  H. Münzberg,et al.  Molecular and anatomical determinants of central leptin resistance , 2005, Nature Neuroscience.

[26]  Alain Favier,et al.  The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. , 2004, Archives of internal medicine.

[27]  J. Manson,et al.  Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. , 2004, JAMA.

[28]  P. Havel.  Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. , 2004, Diabetes.

[29]  T. Funahashi,et al.  Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. , 2003, Diabetes care.

[30]  M. Touvier,et al.  Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. , 2013, American journal of epidemiology.

[31]  Wolfgang Rathmann,et al.  The potential of novel biomarkers to improve risk prediction of type 2 diabetes , 2013, Diabetologia.

[32]  M. Pencina,et al.  A SAS ® Macro to Compute Added Predictive Ability of New Markers Predicting a Dichotomous Outcome , 2010 .

[33]  B. Balkau,et al.  Predicting Diabetes: Clinical, Biological, and Genetic Approaches Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) , 2008 .